IP Library Granted Patent US 10,392,609
Granted Patent B2
US 10,392,609 · App. 15/350,648 · Granted Aug 27, 2019

Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose

Inventors: Nico Luc Marc Callewaert (Hansbeke-Nevele, BE); Wouter Vervecken (Landskouter, BE); Petra Sophie Tiels (Gent-Zwijnaarde, BE); Han Karel Remaut (Boutersem, BE); Kathleen Camilla Telesphore Alida Maria Piens (Ghent, BE)
Assignees: Oxyrane UK Limited; VIB vzw; Universiteit Gent; Vrije Universiteit Brussel
C12N9/2488C07K14/00C12N9/2428C12N9/2465C12P19/04C12P19/14C12P21/00C12P21/005C12Y302/01C12Y302/01003C12Y302/01022Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,392,609
App. No.
15/350,648
Granted
Aug 27, 2019
Kind
B2
Abstract

Described herein are methods and genetically engineered cells useful for uncapping a mannose-6-phosphate residue on an oligosaccharide.

Claims (57)

1. A method for uncapping a mannose-6-phosphate residue on an oligosaccharide, said method comprising

a) providing said oligosaccharide having a mannose-1-phospho-6-mannose linkage; and

b) contacting said oligosaccharide with a mannosidase capable of hydrolyzing said mannose-1-phospho-6-mannose residue to phospho-6-mannose, wherein said mannosidase is a member of glycosyl hydrolase family 92 and wherein said mannosidase does not contain a catalytic acid residue capable of protonating the anomeric oxygen, and

wherein said mannosidase comprises an amino acid sequence having (i) a GVGXXGXGG motif where X is Gly, Ala, Ser, Thr, or Cys; (ii) a VRXE motif, where X is any amino acid other than Pro; (iii) an X 1 YQGX 2 motif, where X 1 is Leu, Ile, Val, Ala, Phe, Tyr or Met, and X 2 is Thr, Ser, or Asn; and (iv) GDXGN, where X can be any amino acid other than Pro, and

wherein said mannosidase comprises an amino acid sequence having at least 90% identity to residues 1 to 774 of SEQ ID NO:50 or an amino acid sequence having at least 95% identity to SEQ ID NO: 50.

2. The method of claim 1 , wherein for said mannosidase, the three dimensional protein coordinates of the atoms in the amino acid side chains located in the minimal catalytic center fall within 1.5 Å deviation of the coordinates of the equivalent atoms in FIG. 33 .

3. The method of claim 1 , wherein said contacting step is performed using a purified mannosidase, a recombinant mannosidase, a cell lysate containing said recombinant mannosidase, or a fungal cell containing said recombinant mannosidase.

4. The method of claim 1 , wherein said oligosaccharide is attached to a protein.

5. The method of claim 4 , wherein said protein is a human protein expressed in a fungal organism.

6. The method of claim 5 , wherein said fungal organism is Yarrowia lipolytica or Arxula adeninivorans.

7. The method of claim 5 , wherein said fungal organism is a methylotrophic yeast.

8. The method of claim 7 , wherein said methylotrophic yeast is Pichia pastoris, Pichia methanolica, Oogataea minuta , or Hansenula polymorpha.

9. The method of claim 5 , wherein said fungal organism is a filamentous fungus.

10. The method of claim 9 , wherein said filamentous fungus is selected from the group consisting of Aspergillus caesiellus, Aspergillus candidus, Aspergillus carneus, Aspergillus clavatus, Aspergillus deflectus, Aspergillus flavus, Aspergillus fumigatus, Aspergillus glaucus, Aspergillus nidulans, Aspergillus niger, Aspergillus ochraceus, Aspergillus oryzae, Aspergillus parasiticus, Aspergillus penicilloides, Aspergillus restrictus, Aspergillus sojae, Aspergillus sydowii, Aspergillus tamari, Aspergillus terreus, Aspergillus ustus , and Aspergillus versicolor.

11. The method of claim 5 , said fungal organism further comprising a nucleic acid encoding a polypeptide capable of promoting mannosyl phosphorylation.

12. The method of claim 5 , wherein said fungal organism is genetically engineered to be deficient in OCH1 (Outer CHain elongation) activity.

13. The method of claim 5 , said fungal organism further comprising a nucleic acid encoding a polypeptide capable of promoting mannosyl phosphorylation, and wherein said fungal organism is genetically engineered to be deficient in OCH1 activity.

14. The method of claim 11 , wherein said polypeptide capable of promoting mannosyl phosphorylation is a MNN4 polypeptide.

15. The method of claim 11 , wherein said polypeptide capable of promoting mannosyl phosphorylation is a P. pastoris PNO1 polypeptide.

16. The method of claim 4 , wherein said protein is a pathogen protein, a lysosomal protein, a growth factor, a cytokine, a chemokine, an antibody or antigen-binding fragment thereof, or a fusion protein.

17. The method of claim 16 , wherein said lysosomal protein is a lysosomal enzyme.

18. The method of claim 17 , wherein said lysosomal enzyme is associated with a lysosomal storage disorder (LSD).

19. The method of claim 18 , wherein said LSD is selected from the group consisting of Fabry's disease, mucopolysaccharidosis I, Farber disease, Gaucher disease, GM1-gangliosidosis, Tay-Sachs disease, Sandhoff disease, GM2 activator disease, Krabbe disease, metachromatic leukodystrophy, Niemann-Pick disease, Scheie disease, Hunter disease, Sanfilippo disease, Morquio disease, Maroteaux-Lamy disease, hyaluronidase deficiency, aspartylglucosaminuria, fucosidosis, mannosidosis, Schindler disease, sialidosis type 1, Pompe disease, Pycnodysostosis, ceroid lipofuscinosis, cholesterol ester storage disease, Wolman disease, Multiple sulfatase deficiency, galactosialidosis, mucolipidosis, cystinosis, sialic acid storage disorder, chylomicron retention disease with Marinesco-Sjögren syndrome, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Danon disease, and Geleophysic dysplasia.

20. The method of claim 18 , wherein said LSD is Pompe disease or Fabry's disease.

21. The method of claim 17 , wherein said lysosomal enzyme is acid alpha glucosidase or alpha galactosidase.

22. The method of claim 1 , wherein said mannosidase comprises a targeting sequence to target the mannosidase to an intracellular compartment.

23. The method of claim 1 , wherein the residue of said mannosidase corresponding to glutamic acid residue Glu 585 of the Bacteroides thetaiotaomicron alpha-1,2-mannosidase Bt3990 is a non-acidic residue.

24. The method of claim 23 , wherein the residue of the mannosidase corresponding to the glutamic acid residue Glu 585 of the Bacteroides thetaiotaomicron alpha-1,2-mannosidase Bt3990 is a threonine or serine residue.

25. The method of claim 1 , wherein said mannosidase is a C. cellulans mannosidase.

26. A method for uncapping a mannose-6-phosphate residue on an oligosaccharide, said method comprising

a) providing said oligosaccharide having a mannose-1-phospho-6-mannose linkage; and

b) contacting said oligosaccharide with a mannosidase capable of hydrolyzing said mannose-1-phospho-6-mannose residue to phospho-6-mannose, wherein said mannosidase is a member of glycosyl hydrolase family 92 and wherein said mannosidase does not contain a catalytic acid residue capable of protonating the anomeric oxygen, and

wherein for said mannosidase, the three dimensional protein coordinates of the atoms in the amino acid side chains located in the minimal catalytic center fall within 1.5 Å deviation of the coordinates of the equivalent atoms in FIG. 33 , and

wherein said mannosidase comprises an amino acid sequence having at least 90% identity to residues 1 to 774 of SEQ ID NO:50 or an amino acid sequence having at least 95% identity to SEQ ID NO: 50.

27. The method of claim 26 , wherein said contacting step is performed using a purified mannosidase, a recombinant mannosidase, a cell lysate containing said recombinant mannosidase, or a fungal cell containing said recombinant mannosidase.

28. The method of claim 26 , wherein said oligosaccharide is attached to a protein.

29. The method of claim 28 , wherein:

said protein is a human protein expressed in a fungal organism; or

said protein is a pathogen protein, a lysosomal protein, a growth factor, a cytokine, a chemokine, an antibody or antigen-binding fragment thereof, or a fusion protein.

30. The method of claim 26 , wherein said mannosidase comprises a targeting sequence to target the mannosidase to an intracellular compartment.

31. The method of claim 26 , wherein:

the residue of said mannosidase corresponding to glutamic acid residue Glu 533 of the Bacteroides thetaiotaomicron alpha-1,2-mannosidase Bt3990 is a non-acidic residue; and/or

the residue of said mannosidase corresponding to glutamic acid residue Glu 585 of the Bacteroides thetaiotaomicron alpha-1,2-mannosidase Bt3990 is a non-acidic residue.

32. The method of claim 26 , wherein said mannosidase is a C. cellulans mannosidase.

33. A method for uncapping a mannose-6-phosphate residue on an oligosaccharide, said method comprising

a) providing said oligosaccharide having a mannose-1-phospho-6-mannose linkage; and

b) contacting said oligosaccharide with a mannosidase capable of hydrolyzing said mannose-1-phospho-6-mannose residue to phospho-6-mannose, wherein said mannosidase is a member of glycosyl hydrolase family 92 and wherein said mannosidase does not contain a catalytic acid residue capable of protonating the anomeric oxygen, and

wherein said mannosidase comprises an amino acid sequence having at least the following residues forming the catalytic center: G71, G72, D355, R405, Q536, N588, Q589, T626, D660 and D662, and

wherein said mannosidase comprises an amino acid sequence having at least 90% identity to residues 1 to 774 of SEQ ID NO:50 or an amino acid sequence having at least 95% identity to SEQ ID NO: 50.

34. The method of claim 33 , wherein for said mannosidase, the three dimensional protein coordinates of the atoms in the amino acid side chains located in the minimal catalytic center fall within 1.5 Å deviation of the coordinates of the equivalent atoms in FIG. 33 .

35. The method of claim 33 , wherein said contacting step is performed using a purified mannosidase, a recombinant mannosidase, a cell lysate containing said recombinant mannosidase, or a fungal cell containing said recombinant mannosidase.

36. The method of claim 33 , wherein said oligosaccharide is attached to a protein.

37. The method of claim 36 , wherein:

said protein is a human protein expressed in a fungal organism; or

said protein is a pathogen protein, a lysosomal protein, a growth factor, a cytokine, a chemokine, an antibody or antigen-binding fragment thereof, or a fusion protein.

38. The method of claim 33 , wherein said mannosidase comprises a targeting sequence to target the mannosidase to an intracellular compartment.

39. The method of claim 33 , wherein said mannosidase is a C. cellulans mannosidase.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2024
From: OXYRANE UK LTD
To: VIB VZW
Reel/Frame 067265/0154 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2016
From: CALLEWAERT, NICO LUC; TIELS, PETRA SOPHIE
To: V1B VZW; UNIVERSITEIT GENT
Reel/Frame 040312/0715 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2016
From: REMAUT, HAN KAREL
To: VIB VZW; VRIJE UNIVERSITEIT BRUSSEL
Reel/Frame 040312/0852 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2016
From: PIENS, KATHLEEN CAMILLA TELESPHORE ALIDA MARIA
To: OXYRANE UK LIMITED
Reel/Frame 040312/0916 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2016
From: VERVECKEN, WOUTER
To: VIB VZW; UNIVERSITEIT GENT; OXYRANE UK LIMITED
Reel/Frame 040312/0969 →
Continuity (3)
Continuation 13499061
Provisional Application 61246847 · Sep 29, 2009
Related Publication 20170226493A1 · Aug 10, 2017